FDG PET/CT evaluation of pathologically proven pulmonary lesions in an area of high endemic granulomatous disease

Ronnie Sebro · Carina Mari Aparici · Miguel Hernandez-Pampaloni

Abstract

Purpose The goal of this study is to assess how reliable the threshold maximum standardized uptake value (maxSUV) of 2.5 on positron emission tomography–computed tomography (PET/CT) is for evaluation of solitary pulmonary lesions in an area of endemic granulomatous disease and to consider other imaging findings that may increase the accuracy of PET/CT.

Materials and methods The staging PET/CT of 72 subjects with solitary pulmonary lesions (nodules (less than 3 cm) or masses (greater than 3 cm)) were retrospectively reviewed. Pathology proven diagnosis from tissue samples was used as the gold standard. Logistic regression was used to assess whether the subject’s age, maxSUV, size of lesion, presence of emphysema, or evidence of granulomatous disease was predictive of malignancy.

Results Malignant lesions were identified in 84.7 % (61/72) of the 72 subjects. A threshold maxSUV of 2.5 had a sensitivity of 95.1 % (58/61), specificity of 45.5 % (5/11), positive predictive value of 90.6 % (58/64), negative predictive value of 62.5 % (5/8) and an accuracy of 87.5 % (63/72). The false negative rate was 4.9 %, and the false positive rate was 54.5 %. All 3 false negatives were less than or equal to 1.0 cm; however, false positives ranged from 1.1 to 5.6 cm. The false negatives had a mean (SD) maxSUV of 2.0 (0.4), whereas the false positives had a mean (SD) maxSUV of 5.6 (3.0). Emphysema was associated with 1.1 higher odds of malignancy, and evidence of granulomatous disease was associated with 0.34 lower odds of benign disease, however, neither was statistically significant (p = 0.92 and p = 0.31, respectively). Higher maxSUV was significantly associated with increased risk of malignancy (p = 8.3 × 10^{-3}). Older age and larger size of lesion were borderline associated with increased risk of malignancy (p = 0.05 and p = 0.07, respectively).

Conclusion In an area of high endemic granulomatous disease, the PET/CT threshold maxSUV of 2.5 retains a high sensitivity (95.1 %) and positive predictive value (90.6 %) for differentiating benign from malignant pulmonary lesions; however, the specificity (45.5) and negative predictive value (62.5) decrease due to increased false positives. The presence of emphysema and absence of evidence of granulomatous disease increases the probability that a pulmonary lesion is malignant; however, these were not statistically significant.

Keywords PET/CT · Solitary pulmonary nodule · Granulomatous disease · Emphysema

Introduction

18-Fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET/CT) is an imaging modality that is often used to help differentiate benign from malignant pulmonary lesions [1]. PET/CT has also been shown to improve the accuracy of staging non-small cell lung cancer [2]. The fusion modality PET/CT has gained popularity because of its higher accuracy for evaluation of
lesions compared to either PET or CT alone [3, 4]. Malignant lesions have been shown to have increased expression of the glucose transporter (GLUT-1) and tend to have increased metabolic activity evidenced by increased FDG uptake [5]. However, several benign conditions have also been noted to have increased metabolic activity including infections, granulomatous disease and tuberculosis [6–8]. The threshold maximum standardized uptake value (maxSUV) of 2.5 has been suggested as having reasonable receiver operator characteristics to differentiate benign from malignant pulmonary lesions [9].

We investigate the performance of PET/CT in subjects from Northern California where there is highly endemic granulomatous disease (coccidioidomycosis) [10]. Unlike several prior series investigating the use of PET/CT, all diagnoses were confirmed by histopathology. The accuracy, sensitivity and specificity of the threshold maxSUV value of 2.5 for evaluation of lesions were calculated. Finally we considered other imaging features that may increase the reader accuracy of PET/CT.

**Materials and methods**

**Subjects**

The study was approved by the Institutional Review Board (IRB) at the University of California, San Francisco Medical Center. The data are derived from retrospective review of the medical records and imaging of 72 subjects who underwent either fine needle aspiration (FNA) or surgical biopsy of solid solitary pulmonary lesions resulting in a definitive pathologic diagnosis and had a PET/CT study performed for evaluation of the solitary pulmonary lesion in the 2 months prior to the surgical biopsy or FNA. All PET/CT studies were performed between January 2010 and November 2011.

**Imaging technique**

All subjects underwent whole body non-contrast enhanced PET/CT, and all scans were acquired using the same PET/CT scanner [General Electric (GE) Discovery 690 (Wisconsin, USA)]. A 64 slice General Electric LightSpeed multi-detector VCT was the Computed Tomography (CT) scanner used in the PET/CT system. The arms were positioned above the subject’s head for CT acquisition, except for subjects with restricted range of movement or shoulder pathology where subject’s arms were positioned at the subject’s sides.

Subjects fasted for at least 6 h prior to the study. CT was acquired from the vertex to the toes without intravenous contrast approximately 60 min following the intravenous administration of 9.0–12.0 mCi (3.33 × 10^2 to 4.44 × 10^2 MBq) of FDG, followed by an emission positron emission tomography (PET) scan. PET images were attenuation corrected using the CT transmission data. Axial, coronal and sagittal PET images with and without attenuation correction, and a rotating three-dimensional (3D) maximum intensity projection (MIP) image, were obtained for study interpretation. The non-attenuated corrected images were reviewed because these images are sometimes more accurate for evaluation of pulmonary nodules [11]. Acquired CT and fused PET/CT images were reviewed alongside the uncorrected and corrected PET images. The blood glucose level was less than 160 mg/dL at the time of FDG injection for all subjects.

**Image interpretation**

All studies were evaluated by a physician certified in Nuclear Medicine by the American Board of Nuclear Medicine (ABNM). The size (maximum dimension) and maximum standardized uptake value (maxSUV) of each pulmonary nodule was recorded. Evidence of prior granulomatous disease (calcified hilar or mediastinal lymph nodes, calcified pulmonary nodules, liver or splenic granulomas) and presence of emphysema were noted.

**Statistics**

Statistics were performed using R v2.9.1 statistical software (www.r-project.org). Exact two-sample tests of proportion were used for comparison of two proportions.

**Results**

The mean (range) age in the cohort was 69.9 (54–91) years. A total of 72 lesions were identified with a diagnosis based on histopathology. The mean (range) lesion size was 3.0 (0.8–11.0) cm. The mean (range) maxSUV was 10.8 (0.8–36.8). 70.8 % (51/72) of subjects had emphysema and 25.0 % (18/72) had evidence of granulomatous disease (Table 1).

Most (84.7 %) of the lesions with histopathological diagnoses were malignant, and most (96.7 %) of these lesions were primary bronchogenic malignancies. The most common malignancies were adenocarcinoma [47.5 % (29/61)], squamous cell carcinoma [32.8 % (20/61)], unspecified non-small cell lung cancer [11.5 % (7/61)] and metastases [3.3 % (2/61)]. Not all of the lesions that were biopsied were malignant. 15.3 % (11/72) of the biopsied lesions were benign. The most common benign lesions that were biopsied were inflammatory lesions [8.3 % (6/72)].
granulomatous lesions (tuberculosis and coccidiodomycosis) [4.2 % (3/72)], non-granulomatous infection [1.4 % (1/72)] and nodular pulmonary amyloidosis [1.4 % (1/72)] (Table 2).

Using a maxSUV threshold of 2.5, 63/72 biopsied lesions were characterized correctly according to biopsy results giving an accuracy of 87.5 %. The sensitivity and specificity using the maxSUV threshold of 2.5 was 95.1 % (58/61) and 45.5 % (5/11), respectively (Table 3). The three false negative lesions (3/72) had a mean (SD) maxSUV of 2.1 (0.4) and a mean (SD) size of 8.7 (1.2) mm. The false positive lesions (6/72) had a mean (SD) maxSUV of 5.6 (3.0) and a mean (SD) size of 24 (17.2) mm.

Older individuals were more likely to have malignant lesions, however, this was borderline statistically significant ($p = 0.05$). Larger lesions were more likely to be malignant, however, this was also borderline statistically significant ($p = 0.07$). Higher metabolic activity measured by maxSUV was significantly associated with increased risk of malignancy ($p = 8.3 \times 10^{-3}$) (Table 4). In the multivariate analysis, the presence of emphysema was associated with an increased risk of malignancy, however, this was not statistically significant ($p = 0.92$). The power of this analysis was limited because most subjects had emphysema. Similarly, evidence of prior granulomatous disease was associated with a decreased risk of malignancy, however, this was not statistically significant ($p = 0.31$).

Figure 1 shows a plot of the maxSUV versus size of pulmonary lesion. There was a positive correlation between the size of the lesion and the maxSUV ($r = 0.71$, $p = 6.2 \times 10^{-7}$) indicating that larger lesions were associated with increased metabolic activity and therefore increased risk of malignancy, however, some of the larger lesions were also benign.

### Discussion

PET/CT remains a useful tool for the evaluation of solid solitary pulmonary lesions. It has been postulated that a solid pulmonary nodule with a maxSUV greater than 2.5 in the right clinical setting should be considered suspicious for malignancy. However, with this maxSUV threshold of 2.5, there are both false positives and false negatives. In our study, we noted far more false positive than false negative results. The increased false positive results were in part related to endemic granulomatous disease. The false negative results were likely related to the small size of the lesion (less than 10 mm). Only one of the six lesions that were less than 10 mm had a maxSUV greater than 2.5. The false positive results were due to infections, including tuberculosis and coccidiodomycosis. These false positive lesions were on average 9.6 mm smaller, but this was not statistically significant ($p = 0.25$), however, the false positive lesions did have significantly lower maxSUV values than the true positive lesions ($p = 8.0 \times 10^{-4}$).

Figure 2 shows a subject with a false positive PET/CT due to a hypermetabolic coccidiodoma.

The accuracy, sensitivity, specificity, negative predictive value and positive predictive value of the maximum SUV threshold of 2.5 in this study were 87.5, 95.1, 45.5, 62.5, and 90.6 %, respectively. The sensitivity and specificity of a test are fixed parameters, which do not change, however, the positive and negative predictive values of a test varies depending on the underlying disease prevalence. The subjects in our study were from Northern California, an area that has a high prevalence of granulomatous disease, which contributed to some of the false positive findings.

Our results are similar to previously published studies. First, we find that bronchogenic carcinoma was the most frequent cause of hypermetabolic solid pulmonary lesions, similar to Ost et al. [8]. The lesion size, age, smoking history and nodule margins are known risk factors for

---

**Table 1** Study sample characteristics

|                | Mean (SD) | Range |
|----------------|-----------|-------|
| Age            | 69.9 (9.0) | 54–91 |
| Sex (Male %)   | 97.2 % (70/72) | –     |
| Size (mm)      | 30.3 (22.0) | 8–110 |
| Maximum SUV    | 10.8 (7.8) | 0.8–36.8 |
| Presence of emphysema (proportion) | 70.8 % (51/72) | –     |
| Evidence of granulomatous disease (proportion) | 25.0 % (18/72) | –     |

**Table 2** Histopathological diagnoses present

| Pathology                          | % (Proportion) |
|------------------------------------|----------------|
| Benign                             |                |
| Inflammatory                       | 8.3 (6/72)     |
| Tuberculosis                       | 2.8 (2/72)     |
| Amyloidosis                        | 1.4 (1/72)     |
| Bronchopneumonia and abscess       | 1.4 (1/72)     |
| Coccidiodoma                       | 1.4 (1/72)     |
| Malignant                          |                |
| Adenocarcinoma                     | 40.3 (29/72)   |
| Squamous cell                      | 27.8 (20/72)   |
| Unspecified NSCLC                  | 9.7 (7/72)     |
| Metastases                         | 2.7 (2/72)     |
| Small cell lung cancer             | 1.4 (1)        |
| Large cell neuroendocrine carcinoma| 1.4 (1)        |
| Sarcomatoid carcinoma              | 1.4 (1)        |
malignancy [8, 12, 13]. In our study, we also find that age (older individuals), and size of lesion (larger lesions) were borderline significant risk factors for nodules being malignant. We also found some evidence that smoking history evidenced by the presence of emphysema was associated with an increased risk of malignancy, however, this was not statistically significant. Li et al. [14] have found that there are increased false positive PET findings in areas with a high prevalence of tuberculosis (TB). Our results also show that there are also increased false positive PET/CT findings in areas with a high prevalence of endemic granulomatous disease.

PET/CT has decreased accuracy in evaluating small pulmonary nodules due to partial volume effect, in particular nodules less than 8 mm [15], and is therefore only recommended by the Fleischner Society for evaluation of pulmonary nodules greater than 8 mm in size or in patients with a history of malignancy [16]. In our study, the false negative results occurred with lesions that were less than 10 mm in size.

This study was done evaluating single time point PET/CTs. Dual time point PET/CT has been proposed as another method of evaluating solitary pulmonary nodules with conflicting evidence. In one study, dual time point PET/CT appeared to be valuable in differentiating benign

---

Table 3: PET/CT maximum SUV threshold of 2.5 performance for characterization of solitary pulmonary nodules

|                | Accuracy (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|----------------|--------------|-----------------|-----------------|---------|---------|
| All (N = 72)   | 87.5 (63/72) | 95.1 (58/61)    | 45.5 (5/11)     | 90.6 (58/64) | 62.5 (5/8) |
| Emphysema (N = 51) | 84.3 (43/51) | 92.9 (39/42)    | 44.4 (4/9)      | 88.6 (39/44) | 57.1 (4/7) |
| Granulomatous disease (N = 18) | 83.3 (15/18) | 92.9 (13/14)    | 50.0 (2/4)      | 86.7 (13/15) | 66.7 (2/3) |
| Emphysema without granulomatous disease (N = 42) | 88.1 (37/42) | 94.4 (34/36)    | 50.0 (3/6)      | 91.9 (34/37) | 60.0 (3/5) |
| Granulomatous disease without emphysema (N = 9) | 100 (9/9) | 100 (8/8) | 100 (1/1) | 100 (8/8) | 100 (1/1) |

PPV: positive predictive value
NPV: negative predictive value

Emphysema—all subjects with emphysema
Emphysema without granulomatous disease—subjects with only emphysema
Granulomatous disease—all subjects with granulomatous disease
Granulomatous disease without emphysema—subjects with only granulomatous disease

Table 4: Logistic regression evaluating predictors of malignancy

| Variable                        | Odds ratio | 95 % CI      | p value |
|---------------------------------|------------|--------------|---------|
| Univariate                      |            |              |         |
| Age                             | 1.10       | (1.00,1.20)  | 0.05*   |
| Size of lesion (mm)             | 1.05       | (1.00, 1.11) | 0.07    |
| MaxSUV                          | 1.47       | (1.10, 1.96) | 8.3 × 10⁻³* |
| Presence of emphysema           | 0.52       | (0.10, 2.65) | 0.43    |
| Evidence of granulomatous disease | 0.52   | (0.13, 2.05) | 0.35    |
| Multivariate*                   |            |              |         |
| Presence of emphysema           | 1.11       | (0.13, 9.19) | 0.92    |
| Evidence of granulomatous disease | 0.34 | (0.04, 2.67) | 0.31    |

* p value ≤0.05

a Multivariate analyses adjusted for age, size of lesion and maximum SUV

---

Fig. 1: Plot of Maximum SUV versus lesion size
from malignant solitary pulmonary nodules in areas of
high prevalence of granulomatous disease [7]. However,
other studies have shown that dual time point PET/CT has
similar accuracy compared to single time point PET/CT
[17, 18], and Chen et al. [6] conclude that dual time point
PET/CT was not useful, especially in areas with a high
prevalence of granulomatous disease [6]. These discrepant
results may be due to differences in technique. The
maximum FDG uptake for lung cancers occurs at around
5 h (300 min) after injection, and therefore dual time
point PET/CT imaging may in some cases appear no
better than single time point PET/CT imaging if the
second imaging is done 120–180 min after injection of
the radiotracer [19].

There are a few limitations to our study. First, the study
was retrospective in nature and therefore subject to case
selection bias. Another limitation of our study was that the
lesions that did not go on to excision/biopsy were excluded
from the analysis. Although this is a limitation, it is also a
strength of this study. Histopathologic proof was used to
determine the diagnosis of each of the pulmonary lesions.
This diminishes uncertainty and potential misdiagnoses
that can occur when criteria such as lack of interval change
on imaging studies are used for indicating the true diag-
oses of the pulmonary lesions. Most of the subjects in the
study were male, which may limit generalizability of the
results. Finally, we use the common maximum SUV
threshold value of 2.5, which has been challenged in the
literature as being too high and not specific enough to rule
in underlying malignancy [20, 21]. While there remains
significant debate around this threshold, at our institution,
all lesions that are not excised/biopsied are followed for at
least 2 years to document stability.

Evaluation of solitary pulmonary nodules remains a
diagnostic challenge. Over 150,000 patients annually present
to their physicians with the diagnostic dilemma of a solitary
pulmonary nodule found either on chest X-ray or chest CT
[22]. Lung cancer has the highest incidence and highest
mortality in the United States [23], and early detection of
lung cancers greatly improves survival [23]. This study
substantiates the use of PET/CT for characterization of solid
pulmonary lesions in subjects from areas with endemic
granulomatous disease; however, there are increased false
positive findings due to granulomatous disease in this setting.

Summary

In an area of high endemic granulomatous disease, the
PET/CT threshold maxSUV of 2.5 retains a high sensitivity
(95.1 %) and positive predictive value (90.6 %) for differ-
entiating benign from malignant pulmonary lesions; how-
ever, the specificity (45.5 %) and negative predictive
value (62.5 %) decrease due to increased false positives.
This suggests that further work needs to be done to assess
how the performance of PET/CT can be improved to
evaluate solid solitary pulmonary lesions in patients from
areas with endemic granulomatous disease. The presence
of emphysema and absence of evidence of granulomatous
disease increases the probability that a pulmonary nodule is
malignant; however, these were not statistically significant
(p = 0.92 and p = 0.31, respectively).

Acknowledgments The authors would like to thank Dr Thor
Johnson and Solandra Craig for their assistance with the preparation
of this manuscript. The authors would also like to thank the anony-
mous reviewers for their valuable comments.

Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.

Fig. 2 Fused PET/CT image (left) and non-attenuated corrected PET image (right) demonstrating an intense FDG uptake in a coccidiodoma
seen in the left lung
References

1. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med. 1994;35(11):1771–6.
2. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.
3. Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007;48(2):214–20.
4. Fletcher JW, Kymes SM, Gould M, Alazraki N, Coleman RE, Lowe VJ, et al. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med. 2008;49(2):179–85.
5. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551–5.
6. Chen CJ, Lee BF, Yao WJ, Cheng L, Wu PS, Chu CL, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol. 2008;191(2):475–9.
7. Huang YE, Lu HI, Liu FY, Huang YJ, Lin MC, Chen CF, et al. Solitary pulmonary nodules differentiated by dynamic F-18 FDG PET in a region with high prevalence of granulomatous disease. J Radiat Res. 2012;53(2):306–12.
8. Ost D, Fein AM, Feinsilver SH. Clinical practice. The solitary pulmonary nodule. N Engl J Med. 2003;348:2535–42.
9. Al-Sugair A, Coleman RE. Applications of PET in lung cancer. Semin Nucl Med. 1998;28:303–19.
10. Huang JY, Bristow B, Shafir S, Sorvillo F. Coccidioidomycosis-associated deaths, United States, 1990–2008. Emerg Infect Dis. 2012;18(11):1723–8.
11. Huang YE, Pu YL, Huang YJ, Chen CF, Pu QH, Konda SD, Appelbaum DE. The utility of the nonattenuation corrected 18F-FDG PET images in the characterization of solitary pulmonary lesions. Nucl Med Commun. 2010;31(11):945–51.
12. MacMahon H, Austin IH, Gamsu G, Herold CI, Jett JR, Naidich DP, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology. 2005;237(2):395–400.
13. Gould MK, Ananth L, Barnett PG, Veterans Affairs SNAP Cooperative Study Group. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest. 2007;131(2):383–8.
14. Li Y, Su M, Li F, Kuang A, Tian R. The value of 18F-FDG-PET/CT in the differential diagnosis of solitary pulmonary nodules in areas with a high incidence of tuberculosis. Ann Nucl Med. 2011;25(10):804–11.
15. Herder GJ, Goldman RP, Hoekstra OS, Comans EF, Teule GJ, Postmus PE, et al. The performance of 18F fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2004;31:1231–6.
16. Khandani AH, Fielding JR. PET in management of small pulmonary nodules. Radiology. 2007;242(3):948–9.
17. Barger RL Jr, Nandalur KR. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol. 2012;19(2):153–8.
18. Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer. 2010;68:66–71.
19. MacDonald K, Searle J, Lyburn I. The role of dual time point FDG PET Imaging in the evaluation of solitary pulmonary nodules with an initial uptake value less than 2.5. Clin Radiol. 2011;66(3):244–50.
20. Fisher RE. PET for the evaluation of solitary pulmonary nodules. J Nucl Med. 2009;50(2):326.
21. Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med. 2006;47:426–31.
22. Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD. The solitary pulmonary nodule. Chest. 2003;123(1 suppl):89S–96S.
23. American Cancer Society. Cancer facts and figures, 2012. http://www.cancer.org/research/cancerfactsfigures/acsf-031941.